AACR21: Bristol Myers looks to build Opdivo's case in early cancer with full data in pre-surgical NSCLC
Checkpoint inhibitors have completely changed the landscape of metastatic, unresectable cancer since their introduction. But one remaining frontier is in patients whose tumors can still be removed, and Bristol Myers Squibb thinks it has a case to be made for PD-1 blocker Opdivo in that setting.
Bristol Myers’ Opdivo given as a neoadjuvant combination with chemo posted a 24% pathological complete response (pCR) rate for patients across the PD-(L)1 expression spectrum with non-small cell lung cancer compared with just 2.2% for chemo alone, according to late breaking Phase III data from the CHECKMATE-816 study presented Saturday at the virtual AACR annual meeting.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.